Cervical cancer control in Latin America: A call to action

Cancer

Volumn 122, Issue 4, 2016, Pages 502-514

  Bychkovsky, Brittany L ^a,b   Ferreyra, Mayra E ^c   Strasser Weippl, Kathrin ^d   Herold, Christina I ^a,b   De Lima Lopes, Gilberto ^e,f   Dizon, Don S ^b   Schmeler, Kathleen M ^g   Del Carmen, Marcela ^h   Randall, Tom C ^h,i   Nogueira Rodrigues, Angelica ^j   De Carvalho Calabrich, Aknar Freire ^k   St Louis, Jessica ^l,m   Vail, Caroline M ^l,m,n   Goss, Paul E ^b,l,m  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Oncology Department   (Argentina)

^d WILHELMINEN HOSPITAL   (Austria)

^e Sao Paulo State Institute of Cancer   (Brazil)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ DANA FARBER HARVARD CANCER CENTER   (United States)

^j FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^k Clinica AMO   (Brazil)

^l Global Cancer Institute   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ UNIVERSITY OF NEW ENGLAND   (United States)

more..

Author keywords

cervical cancer; human papillomavirus (HPV); Latin America; screening; vaccination

Indexed keywords

ACETIC ACID; VIRUS DNA; WART VIRUS VACCINE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

AWARENESS; CANCER CONTROL; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CAPACITY BUILDING; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DRUG COST; DRUG DOSE REGIMEN; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MISCELLANEOUS NAMED GROUPS; MONITORING; MORBIDITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATIENT EDUCATION; PATIENT NAVIGATOR; POPULATION; PRIMARY PREVENTION; PRIMARY TARGET POPULATION; PRIORITY JOURNAL; REVIEW; SCHOOL BASED VACCINATION; SECONDARY TARGET POPULATION; SOUTH AND CENTRAL AMERICA; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; FEMALE; GENETICS; MORTALITY; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VAGINA SMEAR;

ACETIC ACID; CERVIX UTERI; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INDICATORS AND REAGENTS; LATIN AMERICA; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84959142143     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29813     Document Type: Review

References (108)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244-265.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2010 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: IARC; 2014.
3. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
4. Pan American Health Organization. Cervical cancer. http://www.paho.org/hq/index.php?option=com-topics&view=article&id=348&Itemid=40936&lang=en. Accessed July 21, 2014.
5. United Nations. Millennium Development Goals Report 2015. http://www.un.org/millenniumgoals/2015-MDG-Report/pdf/MDG%202015%20rev%20(July%201).pdf. Accessed August 5, 2015.
6. Creative Commons. Syringe images. http://search.creativecommons.org. Accessed March 19, 2015.
7. Hariri S, Dunne E, Saraiya M, Unger E, Markowitz L,. Chapter 5: Human Papillomavirus. (HPV) Manual for the Surveillance of Vaccine-Preventable Diseases. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html. Accessed August 12, 2015.
8. de Sanjose S, Quint WG, Alemany L, et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056.
9. Chesson HW, Dunne EF, Hariri S, Markowitz LE,. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Trans Dis. 2014; 41: 660-664.
10. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S,. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890-907.
11. Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA,. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy. 2011; 31: 280-297.
12. Albero G, Castellsague X, Giuliano AR, Bosch FX,. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis. 2012; 39: 104-113.
13. Joura EA, Giuliano AR, Iversen OE, et al,; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372: 711-723.
14. Garland SM, Hernandez-Avila M, Wheeler CM, et al., Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928-1943.
15. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-1927.
16. Paavonen J, Naud P, Salmeron J, et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-314.
17. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al,; Costa Rica Vaccine Trial and PATRICIA study groups. Efficacy of fewer than 3 doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015; 16: 775-786.
18. Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M,. The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. J Natl Cancer Inst. 2015; 107 (3). pii: dju436.
19. World Health Organization. Summary of the SAGE April 2014 Meeting. http://www.who.int/immunization/sage/meetings/2014/april/report-summary-april-2014/en/. Accessed June 18, 2015.
20. Pan American Health Organization. Technical Advisory Group on Vaccine-Preventable Diseases XXI Meeting: Vaccination: A Shared Responsibility; July 3-5, 2013; Quito, Ecuador. http://www.paho.org/immunization/toolkit/resources/tech-recommendations/TAG-2013.pdf. Accessed June 18, 2015.
21. Pan American Health Organization. Cancer in the Americas. Basic Indicators 2013. http://www.paho.org/hq/index.php?option=com-topics&view=article&id=2&Itemid=40735&lang=en. Accessed August 5, 2015.
22. Pan American Health Organization. PAHO Immunization Newsletter December 2014. HPV Vaccine in Chile and Ecuador. http://www.paho.org/hq/index.php?option=com-content&view=article&id=3130:immunization-newsletter&Itemid=3504&lang=en. Accessed April 2, 2015.
23. World Health Organization. HPV Vaccine in Argentina: a leap forward for girls' and women's health. http://www.who.int/features/2013/argentina-hpv-vaccine/en/. Accessed March 3, 2015.
24. Munoz N,. Progress in HPV vaccine introduction in Latin America. https://www.g-o-c.org/uploads/12nov-hpvtoday.pdf. Accessed August 5, 2015.
25. Stokley S, Jeyarajah J, Yankey D, et al,; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014; 63: 620-624.
26. McClure CA, MacSwain MA, Morrison H, Sanford CJ,. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada. Vaccine. 2015; 33: 1786-1790.
27. Public Health Agency of Canada. Canada Communicable Disease Report. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php#a5. Accessed August 5, 2015.
28. Goss PE, Lee BL, Badovinac-Crnjevic T, et al., Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013; 14: 391-436.
29. Pan American Health Organization, World Health Organization, Healthy Caribbean Coalition. Situational analysis of cervical cancer prevention and control in the Caribbean: results from a 2013 assessment of country policies and services for HPV vaccination ccs, diagnosis and treatment December, 2013. http://www.paho.org/hq/index.php?option=com-docman&task=doc-view&gid=23829&Itemid=. Accessed November 2, 2015.
30. Soneji S, Fukui N,. Socioeconomic determinants of cervical cancer screening in Latin America. Rev Panam Salud Publica. 2013; 33: 174-182.
31. Shastri SS, Mittra I, Mishra GA, et al., Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 2014; 106: dju009.
32. International Agency for Research on Cancer. Handbooks of Cancer Prevention. Vol 10: Cervix cancer screening. http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/index.php. Accessed August 5, 2015.
33. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL,. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136: 189-197.
34. US Preventive Services Task Force. Screening for cervical cancer, clinical considerations. http://www.uspreventiveservicestaskforce.org/3rduspstf/cervcan/cervcanrr.htm#clinical. Accessed August 5, 2015.
35. Sankaranarayanan R, Nene BM, Shastri SS, et al., HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360: 1385-1394.
36. US Food and Drug Administration. FDA News Release: FDA approves first human papillomavirus test for primary cervical cancer screening. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394773.htm. Accessed September 9, 2014.
37. Tao X, Griffith CC, Zhou X, et al., History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China. Cancer (Cancer Cytopathol). 2015; 123: 421-427.
38. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R,. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013; 2: 35.
39. Rijkaart DC, Berkhof J, Rozendaal L, et al., Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012; 13: 78-88.
40. Arbyn M, Sankaranarayanan R, Muwonge R, et al., Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008; 123: 153-160.
41. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A,. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009; 45: 2640-2648.
42. Anttila A, von Karsa L, Aasmaa A, et al., Cervical cancer screening policies and coverage in Europe. Eur J Cancer. 2009; 45: 2649-2658.
43. Papanicolaou GN, Traut HE,. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941; 42: 193-206.
44. US Preventive Services Task Force. Cervical Cancer: screening. Recommendation summary. http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/cervical-cancer-screening. Accessed September 9, 2014.
45. Blake KD, Ottenbacher AJ, Finney Rutten LJ, et al., Predictors of human papillomavirus awareness and knowledge in 2013: gaps and opportunities for targeted communication strategies. Am J Prev Med. 2015; 48: 402-410.
46. Perkins RB, Langrish SM, Cotton DJ, Simon CJ,. Maternal support for human papillomavirus vaccination in Honduras. J Womens Health (Larchmt). 2011; 20: 85-90.
47. Petrocy A, Katz ML,. Cervical cancer and HPV: knowledge, attitudes, beliefs and behaviors among women living in Guatemala. J Health Care Poor Underserved. 2014; 25: 624-636.
48. Blackman E, Thurman N, Halliday D, et al., Multicenter study of human papillomavirus and the human papillomavirus vaccine: knowledge and attitudes among people of African descent. Infect Dis Obstet Gynecol. 2013; 2013: 428582.
49. Fernandez ME, Le YC, Fernandez-Espada N, et al., Knowledge, attitudes and beliefs about human papillomavirus vaccination among Puerto Rican mothers and daughters, 2010: a qualitative study. Prev Chronic Dis. 2014; 11: E212.
50. World Health Organization. Department of Immunization, Vaccines and Biologicals (IVB). http://apps.who.int/immunization/sage/meetings/2013/november/SAGE-yellow-book-November-2013.pdf. Accessed August 5, 2015.
51. World Health Organization. WHO Vaccine-Preventable Diseases: monitoring system. 2014 Global Summary. http://apps.who.int/immunization-monitoring/globalsummary. Accessed August 5, 2015.
52. Cervical Cancer Action (CCA). Progress in Cervical Cancer Prevention: The CCA Report Card. http://cervicalcanceraction.org/pubs/pubs.php#reportcard. Accessed August 5, 2015.
53. de Sanjose S, Serrano B, Castellsague X, et al., Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012; 30 (suppl 4): D1-D83, vi.
54. Pan American Health Organization. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. http://www.paho.org/hq/index.php?option=com-content&view=article&id=9394&. Accessed August 5, 2015.
55. Aday LA, Andersen RA,. Framework for the study of access to medical care. Health Serv Res. 1974; 9: 208-220.
56. Teixeira LA,. From gynaecology offices to screening campaigns: a brief history of cervical cancer prevention in Brazil [in English, Portuguese]. Hist Cienc Saude Manguinhos. 2015; 22: 221-239.
57. Stormo AR, Espey D, Glenn J, et al., Findings and lessons learned from a multi-partner collaboration to increase cervical cancer prevention efforts in Bolivia. Rural Remote Health. 2013; 13: 2595.
58. Carmo CC, Luis RR,. Survival of a cohort of women with cervical cancer diagnosed in a Brazilian cancer center. Rev Saude Publica. 2011; 45: 661-667.
59. Mascarello KC, Zandonade E, Amorim MH,. Survival analysis of women with cervical cancer treated at a referral hospital for oncology in Espírito Santo State, Brazil, 2000-2005. Cad Saude Publica. 2013; 29: 823-831.
60. Pardo C, Cendales R,. Survival analysis of cervical cancer patients [in Spanish]. Biomedica. 2009; 29: 437-447.
61. Sepulveda VP, Gonzalez CP, Napolitano RC, et al., Cancer de cuello uterino: sobrevida a 3 y 5 anos en Hospital San Jose. Rev Chil Obstet Ginecol. 2008; 73: 151-154.
62. Quinn MA, Benedet JL, Odicino F, et al., Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 (suppl 1): S43-S103.
63. Thuler LC, de Aguiar SS, Bergmann A,. Determinants of late stage diagnosis of cervical cancer in Brazil [in Portuguese]. Rev Bras Ginecol Obstet. 2014; 36: 237-243.
64. National Cancer Institute. SEER Stat Fact Sheets: cervix uteri cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed January 21, 2015.
65. Instituto Nacional de Cancer Jose Alencar Gomes da Silva. Controle do Cancer do Colo de Utero. http://www2.inca.gov.br/wps/wcm/connect/acoes-programas/site/home/nobrasil/programa-nacional-controle-cancer-colo-utero/indicadores/. Accessed August 5, 2015.
66. Murillo R, Wiesner C, Cendales R, Pineros M, Tovar S,. Comprehensive evaluation of cervical cancer screening programs: the case of Colombia. Salud Publica Mex. 2011; 53: 469-477.
67. Cendales R, Wiesner C, Murillo RH, et al., Quality of vaginal smear for cervical cancer screening: a concordance study. Biomedica. 2010; 30: 107-115.
68. Lazcano-Ponce EC, Alonso de Ruiz P, Martinez-Arias C, et al., Reproducibility study of cervical cytopathology in Mexico: a need for regulation and professional accreditation. Diagn Cytopathol. 1997; 17: 20-24.
69. Carreon JD, Sherman ME, Guillen D, et al., CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007; 26: 441-446.
70. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007; 11: 201-222.
71. Navarro C, Fonseca AJ, Sibajev A, et al., Cervical cancer screening coverage in a high-incidence region. Rev Saude Publica. 2015; 49: 17.
72. Buenos Aires Ciudad. Campana para la deteccion del Cancer Genito Mamario en el Hospital Maria Curie. http://www.buenosaires.gob.ar/noticias/campana-para-la-deteccion-del-cancer-genito-mamario-en-el-hospital-maria-curie. Accessed August 5, 2015.
73. Andrus JK, Toscano CM, Lewis M, et al., A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep. 2007; 122: 811-816.
74. Pandhi D, Sonthalia S,. Human papilloma virus vaccines: current scenario. Indian J Sex Transm Dis. 2011; 32: 75-85.
75. Techakehakij W, Feldman RD,. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine. 2008; 26: 6258-6265.
76. Pan American Health Organization. Revolving fund prices. http://www.paho.org/hq/index.php?option=com-content&view=article&id=9561&Itemid=40714&lang=en. Accessed August 5, 2015.
77. GAVI. Human papillomavirus vaccine support. http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support/. Accessed August 5, 2015.
78. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY,. Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008; 26: 4080-4093.
79. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY,. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008; 26 (suppl 11): L59-L72.
80. Colantonio L, Gomez JA, Demarteau N, et al., Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine. 2009; 27: 5519-5529.
81. Aponte-Gonzalez J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW,. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One. 2013; 8: e80639.
82. Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N,. Cost-effectiveness of HPV vaccination in Belize. Vaccine. 2015; 33 (suppl 1): A174-A181.
83. Gomez JA, Lepetic A, Demarteau N,. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health. 2014; 14: 1222.
84. Goldie SJ, Kim JJ, Kobus K, et al., Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007; 25: 6257-6270.
85. Kim JJ, Andres-Beck B, Goldie SJ,. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007; 97: 1322-1328.
86. Olsen J, Jorgensen TR,. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Alloc. 2015; 13: 4.
87. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009; 84: 118-131.
88. Tabrizi SN, Brotherton JM, Kaldor JM, et al., Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 14: 958-966.
89. Matthijsse SM, Hontelez JA, Naber SK, et al., The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination. Vaccine. 2015; 33: 5357-5364.
90. Horn J Damm O, Kretzchmar ME, et al., Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013; 31: 2372-2380.
91. Kellard K, Myers P,. Evaluation of the National HPV Vaccination Program Campaign. http://hpv.health.gov.au/wp-content/uploads/2013/01/HPV-Vaccination-Campaign-Evaluation-FINAL-171213-D13-2437752.pdf. Accessed August 6, 2015.
92. Bowyer HL, Dodd RH, Marlow LA, Waller J,. Association between human papillomavirus vaccine status and other cervical cancer risk factors. Vaccine. 2014; 32: 4310-4316.
93. Fregnani JH, Carvalho AL, Eluf-Neto J, et al., A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One. 2013; 8: e62647.
94. UNESCO. 22.1 million children and adolescents in Latin America and the Caribbean are not in school or at serious risk of dropping out. http://www.unesco.org/new/en/education/themes/strengthening-education-systems/inclusive-education/single-view/news/221-million-children-and-adolescents-in-the-region-are-not-in-school-or-at-serious-risk-of-dropping-out/. Accessed August 6, 2015.
95. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep. 2013; 62: 591-595.
96. Penny M, Bartolini R, Mosqueira NR, et al., Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine. 2011; 29: 5022-5030.
97. Ak A, Heier JL, Wardell CL, et al., Improving the Pan American Health Organization's vaccine supply chain. http://hhscenter.gatech.edu/sites/default/files/ImprovingPAHOsVaccineSupplyChainpaper.pdf. Accessed November 18, 2015.
98. Pan American Health Organization. A situational analysis of cervical cancer in Latin America and the Caribbean. http://screening.iarc.fr/doc/pcc-cc-sit-lac.pdf. Accessed August 5, 2015.
99. Paolino M, Arrossi S,. Analysis of the reasons for abandoning the follow-up and treatment process in women with pre-cancerous cervical lesions in the province of Jujuy: implications for health management [in Spanish]. Salud Colect. 2012; 8: 247-261.
100. Garrido JL,. Screening of cervical cancer: 27 years experience in six Republics of Panama. Clin Exp Obstet Gynecol. 2012; 39: 343-345.
101. Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ,. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues. 2010; 20: 35-42.
102. Arrossi S, Thouyaret L, Herrero R, et al,; EMA Study team. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health. 2015; 3: e85-e94.
103. Coleman MA, Levison J, Sangi-Haghpeykar H,. HPV vaccine acceptability in Ghana, West Africa. Vaccine. 2011; 29: 3945-3950.
104. Ruoti de Garcia de Zuniga M, Arrom de Fresco CH, Ruoti Cosp, M, et al., Knowledge, attitudes and practices on the Papanicolaou smear test (PAP) in pregnant women attending public hospitals of the Department of Alto Parana, Paraguay. http://scielo.iics.una.py/scielo.php?script=sci-arttext&pid=S1812-95282008000200008&lng=es&nrm=iso. Accessed August 6, 2015.
105. Battaglia TA, Bak SM, Heeren T, et al., Boston Patient Navigation Research Program: the impact of navigation on time to diagnostic resolution after abnormal cancer screening. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1645-1654.
106. Charlot M, Santana MC, Chen CA, et al., Impact of patient and navigator race and language concordance on care after cancer screening abnormalities. Cancer. 2015; 121: 1477-1483.
107. Suarez E, Prieto M,. Cervical cancer: the Chilean perspective. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 (suppl 1): S235-S238.
108. Katz IT, Wright AA,. Preventing cervical cancer in the developing world. N Engl J Med. 2006; 354: 1110.